Europe Forced Depo-Provera Brain-Tumor Warnings Years Before the US — While Pfizer Stayed Silent

Depo-Provera and the Brain-Tumor Warning Pfizer Added Abroad — but Not in America Until 2025

By May 2026, litigation over the contraceptive injection Depo-Provera had become one of the fastest-growing pharmaceutical mass torts in the country. The federal multidistrict litigation contained 5,549 cases as of May 14, 2026, with more than 700 additional filings spread across state courts in Delaware, New York, California and elsewhere. The plaintiffs are largely women who used the shot for years and were later diagnosed with meningioma, a tumor of the membranes surrounding the brain and spinal cord.

The Science

The litigation accelerated after a 2024 study published in the BMJ. Examining roughly 108,000 women, French researchers reported a 5.55 odds ratio linking prolonged use of the medroxyprogesterone-based injection to meningioma — among the strongest statistical associations seen in any pharmaceutical tort case. The biological plausibility is not new: as far back as 1983, researchers identified high concentrations of progesterone receptors in meningioma cells.

The Warning Gap

The central allegation is one of selective disclosure. European and Canadian regulators required Pfizer to add meningioma warnings to Depo-Provera labels years before US patients got the same information — the US label was not updated until December 2025. That regulatory gap is the core of the plaintiffs' claim: the company possessed and acted on the risk in some markets while American women received no comparable warning.

Where It Stands

With thousands of consolidated cases and a strong epidemiological anchor, the Depo-Provera MDL is positioned as a major test of failure-to-warn liability. The question the documents will answer is the familiar one: what did the manufacturer know, and why did the warning reach women in Europe and Canada years before it reached women in the United States.